Apollomics, Inc. (NASDAQ:APLM) Sees Large Growth in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 4,100 shares, a growth of 57.7% from the August 15th total of 2,600 shares. Based on an average trading volume of 21,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Apollomics in a report on Thursday, June 1st.

Apollomics Price Performance

NASDAQ:APLM traded up $0.16 during trading hours on Friday, hitting $4.06. 7,384 shares of the stock traded hands, compared to its average volume of 95,242. The firm has a 50 day moving average of $5.06. Apollomics has a 1 year low of $3.71 and a 1 year high of $49.00.

Hedge Funds Weigh In On Apollomics

A number of hedge funds have recently made changes to their positions in APLM. George Kaiser Family Foundation purchased a new position in shares of Apollomics in the first quarter worth $16,238,000. Clear Street LLC purchased a new position in shares of Apollomics during the first quarter valued at about $165,000. Geode Capital Management LLC purchased a new position in shares of Apollomics during the first quarter valued at about $325,000. Exchange Traded Concepts LLC purchased a new position in shares of Apollomics during the second quarter valued at about $166,000. Finally, Levin Capital Strategies L.P. purchased a new stake in Apollomics in the 2nd quarter worth about $62,000. Institutional investors own 1.62% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain.